EHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Encompass Health Corp (EHC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and recent expansion efforts outweigh the negative insider trading trends. The technical indicators and options data do not suggest immediate concerns, making this a solid long-term investment opportunity.
The MACD is positive and contracting, indicating a potential continuation of the current trend. RSI is neutral at 51.896, suggesting no overbought or oversold conditions. Moving averages are converging, and the stock is trading near its pivot level of 106.867, with support at 104.582 and resistance at 109.151.
Barclays raised the price target to $153 with an Overweight rating.
Strong Q4 financial performance with revenue up 9.94% YoY and net income up 21.32% YoY.
Expansion with a new 49-bed rehabilitation hospital in South Carolina, indicating growth in operations.
Insider selling has increased significantly by 13423.86% over the last month.
No recent congress trading data or significant hedge fund activity.
In Q4 2025, revenue increased by 9.94% YoY to $1.5446 billion, net income rose by 21.32% YoY to $145.7 million, EPS grew by 21.19% YoY to 1.43, and gross margin improved slightly to 90.23%.
Barclays raised the price target to $153 from $150 and maintained an Overweight rating, reflecting strong confidence in the company's future performance.
